Larissa Schwarzkopf1, Margarethe Wacker2, Rolf Holle3, Reiner Leidl4, Christian Günster5, Jürgen-Bernhard Adler6, Rudolf Maria Huber7. 1. Helmholtz Zentrum München, Institute of Health Economics and Health Care Management, Comprehensive Pneumology Center Munich (CPC-M), Member of the German Center for Lung Research (DZL), Ingolstaedter Landstrasse 1, 85764 Neuherberg, Germany. Electronic address: l.schwarzkopf@helmholtz-muenchen.de. 2. Helmholtz Zentrum München, Institute of Health Economics and Health Care Management, Comprehensive Pneumology Center Munich (CPC-M), Member of the German Center for Lung Research (DZL), Ingolstaedter Landstrasse 1, 85764 Neuherberg, Germany. Electronic address: margarethe.wacker@helmholtz-muenchen.de. 3. Helmholtz Zentrum München, Institute of Health Economics and Health Care Management, Comprehensive Pneumology Center Munich (CPC-M), Member of the German Center for Lung Research (DZL), Ingolstaedter Landstrasse 1, 85764 Neuherberg, Germany. Electronic address: holle@helmholtz-muenchen.de. 4. Helmholtz Zentrum München, Institute of Health Economics and Health Care Management, Comprehensive Pneumology Center Munich (CPC-M), Member of the German Center for Lung Research (DZL), Ingolstaedter Landstrasse 1, 85764 Neuherberg, Germany. Electronic address: leidl@helmholtz-muenchen.de. 5. Wissenschaftliches Institut der AOK (WIdO), Forschungsbereich Integrierte Analysen, Rosenthaler Straße 31, 10178 Berlin, Germany. Electronic address: Christian.Guenster@wido.bv.aok.de. 6. Wissenschaftliches Institut der AOK (WIdO), Forschungsbereich Integrierte Analysen, Rosenthaler Straße 31, 10178 Berlin, Germany. Electronic address: Juergen-Bernhard.Adler@wido.bv.aok.de. 7. Ludwig-Maximilians-Universität München, University Hosital, Division of Respiratory Medicine and Thoracic Oncology, Thoracic Oncology Centre Munich, Comprehensive Pneumology Center Munich (CPC-M), Member of the German Center for Lung Research (DZL), Ziemssenstr. 1, 80336 München, Germany. Electronic address: Huber@med.uni-muenchen.de.
Abstract
OBJECTIVES: Although lung cancer is of high epidemiological relevance in Germany, evidence on its economic implications is scarce. Sound understanding of current care structures and associated expenditures is required to comprehensively judge the additional benefit of novel interventions in lung cancer care. Adopting a payer perspective, our study aims to analyze expenditures for individuals with incident lung cancer. MATERIAL AND METHODS: Patients with an initial diagnosis of lung cancer (ICD-10 code C34) in 2009 were searched in a large, nationwide base of health insurance claims data and grouped according to initial treatment (Surgery, Chemotherapy/Radiotherapy, No specific treatment). All-cause SHI and lung cancer-related spending was assessed for a patient-individual three-year time frame after initial diagnosis. Expenditures per case and expenditures per year survived were calculated via Generalized Linear Gamma Models adjusted for age, gender, living region, baseline metastases, multiple tumors and initial treatment regimen using time under observation as a weighting factor. RESULTS: 17,478 individuals were identified. Lung cancer-related expenditures peaked within the first six months after initial diagnosis. Following, they declined subsequently and so did their share in all-cause SHI spending. Lung cancer-related expenditures per case were estimated at €20,400 (53% of all-cause expenditures) with a huge variance according to initial treatment regimen [ SURGERY: €20,400, Chemotherapy/Radiotherapy: €26,300, No specific treatment: €4200]. Cost per year survived amounted to €15,500 (55% of all cause expenditures) [ SURGERY: €11,600, Chemotherapy/Radiotherapy: €20,200, No specific treatment: €7600]. CONCLUSION: Analyses of lung cancer-related expenditures need to take into account treatment strategies and survival. Our study is representative for a large share of the population and provides detailed, patient-level information on costs of care and their compilation. Results render estimates available for the cost of lung cancer e.g. for budget impact analyses, cost-effectiveness analyses of screening and prevention schemes, or prognostic models of life-time expenditures per lung cancer case.
OBJECTIVES: Although lung cancer is of high epidemiological relevance in Germany, evidence on its economic implications is scarce. Sound understanding of current care structures and associated expenditures is required to comprehensively judge the additional benefit of novel interventions in lung cancer care. Adopting a payer perspective, our study aims to analyze expenditures for individuals with incident lung cancer. MATERIAL AND METHODS:Patients with an initial diagnosis of lung cancer (ICD-10 code C34) in 2009 were searched in a large, nationwide base of health insurance claims data and grouped according to initial treatment (Surgery, Chemotherapy/Radiotherapy, No specific treatment). All-cause SHI and lung cancer-related spending was assessed for a patient-individual three-year time frame after initial diagnosis. Expenditures per case and expenditures per year survived were calculated via Generalized Linear Gamma Models adjusted for age, gender, living region, baseline metastases, multiple tumors and initial treatment regimen using time under observation as a weighting factor. RESULTS: 17,478 individuals were identified. Lung cancer-related expenditures peaked within the first six months after initial diagnosis. Following, they declined subsequently and so did their share in all-cause SHI spending. Lung cancer-related expenditures per case were estimated at €20,400 (53% of all-cause expenditures) with a huge variance according to initial treatment regimen [ SURGERY: €20,400, Chemotherapy/Radiotherapy: €26,300, No specific treatment: €4200]. Cost per year survived amounted to €15,500 (55% of all cause expenditures) [ SURGERY: €11,600, Chemotherapy/Radiotherapy: €20,200, No specific treatment: €7600]. CONCLUSION: Analyses of lung cancer-related expenditures need to take into account treatment strategies and survival. Our study is representative for a large share of the population and provides detailed, patient-level information on costs of care and their compilation. Results render estimates available for the cost of lung cancer e.g. for budget impact analyses, cost-effectiveness analyses of screening and prevention schemes, or prognostic models of life-time expenditures per lung cancer case.
Authors: Phuong Bich Tran; Joseph Kazibwe; Georgios F Nikolaidis; Ismo Linnosmaa; Mieke Rijken; Josefien van Olmen Journal: BMC Med Date: 2022-07-19 Impact factor: 11.150
Authors: Veronika J Wirtz; Hans V Hogerzeil; Andrew L Gray; Maryam Bigdeli; Cornelis P de Joncheere; Margaret A Ewen; Martha Gyansa-Lutterodt; Sun Jing; Vera L Luiza; Regina M Mbindyo; Helene Möller; Corrina Moucheraud; Bernard Pécoul; Lembit Rägo; Arash Rashidian; Dennis Ross-Degnan; Peter N Stephens; Yot Teerawattananon; Ellen F M 't Hoen; Anita K Wagner; Prashant Yadav; Michael R Reich Journal: Lancet Date: 2016-11-08 Impact factor: 79.321
Authors: Anja Thronicke; Thomas Reinhold; Philipp von Trott; Christian Grah; Burkhard Matthes; Harald Matthes; Friedemann Schad Journal: PLoS One Date: 2020-07-27 Impact factor: 3.240
Authors: Hae-Young Park; Jinseub Hwang; Do-Hyang Kim; Soo Min Jeon; Sun Ha Choi; Jin-Won Kwon Journal: BMC Cancer Date: 2020-09-03 Impact factor: 4.430